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Graphical abstract 
 
Abstract 
This study investigates the stability of typically complex multi-component hydrophilic solid 
dispersions that could be used in a clinical application. Felodipine solid dispersions in two 
types of blends consisting of PEG, PEO and Tween 80 or Vit E TPGS were prepared by hot 
melt-injection moulding (HMIM) across a range of drug loadings and subjected to a range of 
storage conditions. Microscopy, thermal analysis, spectroscopy and powder X-ray diffraction 
were used to characterize the systems. The semi-solid surfactant TPGS showed a better 
solubilizing effect on the drug than the liquid surfactant Tween 80 in the fresh state and offered 
some degree of protection over the chemical degradation of PEG/PEO. Better storage stability 
was observed for the systems with low drug loading. Crystallization of a new metastable 
polymorphic form of felodipine in the patches with drug loadings at and above the saturation 
point was observed. Quantitative comparison of the data sets was achieved by a normalisation 
process and calculation of statistical variance. TPGS containing patches were more sensitive 
to the aging process than Tween containing patches.  For both surfactants, such instability is 
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more responsive to the storage temperature than humidity. This study established a 
methodology for probing the complex stabilities of multi-component dispersions.        
Keywords: 
Hot melt extrusion, injection moulding, surfactants, solid dispersions, physical stability, 
polymorph 
 
 
 
 
 
 
Introduction  
Surfactants, such as Tween 80 and TPGS, have been suggested for use as plasticizers in hot 
melt extruded solid dispersions to ease the extrusion process (Ghebremeskel et al., 2007; 
Goddeeris et al., 2008; Morris et al., 1992; Repka and McGinity, 2000, 2001). Recently it has 
also been reported that the addition of significant amount of surfactant can also improve the 
solubility of drugs in the matrix by creating phase separated surfactant rich drug compartments 
in which the drug is soluble (Alhijjaj et al., 2015; Alhijjaj et al., 2016). In some cases, the 
surfactants have been reported to be responsible for destabilizing the drug and cause 
crystallization of drug from the dispersions during storage (Galop, 2005; Ghebremeskel et al., 
2006; Janssens et al., 2008; Wang et al., 2005).  The mechanism of this destabilizing effect has 
been mainly attributed to the low Tg of such materials (Ghebremeskel et al., 2006; Janssens et 
al., 2008; Mosquera-Giraldo et al., 2014). However, the guidance for surfactant selection and 
control such destabilizing effects have been not fully developed. This study aims to contribute 
to a fuller understanding of the destabilization effect of the use of surfactants in hot melt 
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extruded formulations by investigating the stability of two types surfactant-containing hot-melt 
injection moulded (HMIM) patches.  
 
Whilst simple binary model systems can be of great value in understanding basic principles of 
stabilities of solid dispersions, practical formulations used in real clinical applications are often 
multi-component systems. It is clear that the likely behaviour of a clinically realistic 
formulation is going to be complicated. Therefore, this study systematically investigates such 
systems in order to be in a better position to predict how actual practical formulations will 
behave. The multi-component dispersion based patches described here are prepared using low 
temperature and single step processing without the use of organic solvents. They are 
mucoadhesive and could be applied clinically as buccal patches for improving the 
bioavailability of felodipine by bypassing hepatic metabolism which can remove up to 84% of 
the administered dose (Edgar et al., 1985). The formulations contained a mixture of 
polyethylene glycol (PEG), polyethylene oxide (PEO) and Tween 80 or D-tocopheryl 
polyethylene glycol 100 succinate (TPGS) in the ratio 4:3:3. This ratio was kept constant with 
felodipine loadings of 10, 20 and 30% w/w. The patches containing PEG/PEO and Tween 80 
were abbreviated as CM1 while the ones containing PEG/PEO and TPGS were abbreviated as 
CM2. Previously the co-existences of multiple phases were identified in these multi-component 
patches (Alhijjaj et al., 2015; Alhijjaj et al., 2016). These phases are a surfactant rich phase 
containing drug and crystalline and amorphous polymer, amorphous and crystalline polymer 
phase which may also contain some surfactant and drug. The relationships between the phases 
are likely to change on storage as a result of the tendency to move to an equilibrium condition 
with time and the effects of temperature and humidity. If the drug is heterogeneously 
distributed at a microscopic level (Alhijjaj et al., 2015; Alhijjaj et al., 2016) there could be 
multiple drug crystallisation mechanisms which could result in polymorphic forms of the drug. 
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In addition, the stability of each excipient may also impact on the overall stability of the 
formulations. For example, the crystalline PEG/PEO phase can exist in more than one 
crystalline form: a folded form and a linear form (Buckley and Kovacs, 1976; Craig, 1995). 
Changes of PEG/PEO from a less folded form to folded form on aging could be the secondary 
cause of drug instability as changes in crystallinity and crystal thickening on storage have been 
reported in literature (Bley et al., 2010; Damian et al., 2002; Dordunoo et al., 1997; Duong et 
al., 2015; Papageorgiou et al., 2006; Weuts et al., 2005). Taking into consideration of all the 
variables, this study first investigated the effects of the surfactants on the stability of the multi-
component drug-free carrier systems. The impacts of drug incorporation on the stability of the 
carrier were then analyzed. Finally the effects of surfactants on the drug recrystallization were 
studied. The three streams of data with the use of data normalisation and variance analyses of 
the high quantity of thermal data allowed the analysis of the interconnected relationship 
between the stability of the excipients and the stability of the drug in a semi-crystalline multi-
component dispersion.  
 
Materials and methods 
Materials 
The model drug, felodipine, was purchased from Afine Chemicals Ltd (Hangzhou, China). 
Polysorbate (Tween® 80) with a molecular weight of 1310 g/mole and phosphorus pentoxide 
(P2O5) with a purity of 99% were purchased from Sigma-Aldrich (Dorset, UK). Polyethylene 
glycol (PEG) 4000 with an average molecular weight of 4060 g/mole was supplied from 
Sigma-Aldrich (Poole, UK). Polyethylene oxide (PEO) WSR 1105 with an average molecular 
weight of 900,000 g/mole was kindly donated by Colorcon Ltd (Dartford, UK). Vitamin E 
TPGS with a molecular weight of 1513 g/mole was kindly donated by BASF (Ludwigshafen, 
Germany). NaCl (≥ 99.0 %) was purchased from Thermo Fisher Scientific (Geel, Belgium). 
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Preparation of placebo and felodipine loaded HMIM patches 
A co-rotating twin screw bench-top hot melt extruder (HAAK MiniLab II Micro Compounder, 
Thermo Electron, Karlsruhe, Germany) with an injection moulding apparatus (HAAKE 
MiniJet System, Thermo Electron Corporation, Karlsruhe, Germany) was used in the 
fabrications of placebo and felodipine loaded solid dispersions. The injection mould allowed 
the production of patches with a final geometry of 25 mm × 25 mm × 0.5 mm. Two sets of 
formulations containing either Tween 80 (abbreviated as CM1) or TPGS (abbreviated as CM2) 
were prepared. Placebos and patches with 10, 20 and 30% w/w drug loadings were formulated 
with the PEG/PEO/surfactant weight ratios of 40/30/30, 36/27/27, 32/24/24 and 28/21/21, 
respectively. Before extrusion, physical mixtures of the formulations were prepared at different 
drug loadings by initially mixing of crystalline felodipine with either liquid Tween 80 or the 
molten TPGS (65 °C) followed by the addition of the other excipients and all the components 
of formulations were mixed thoroughly using a mortar and pestle for at least 2 minutes at room 
temperature. These mixtures were then fed into the extruder operating at a barrel temperature 
of 65 °C and a screw rotation of 100 rpm with 5 minutes of residence time. After extrusion, the 
extruded soft masses were loaded into the pre-heated cylinder of the injection moulding 
apparatus (65 °C).  The materials were injected into the patch pre-heated mould (65 °C) under 
300 bars pressure for 20 seconds. The patches were collected after being cooled inside the 
mould for 1 hour at ambient temperature.  
 
Storage conditions of the dispersion patches 
After preparation, the placebo and drug loaded patches were immediately stored in four 
different conditions for 3-month stability testing. The four conditions are abbreviated as A, B, 
C and D conditions and they refer to room temperature with 0% relative humidity (RH), room 
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temperature with 75% RH, 40 ºC with 0% RH, and 40 ºC with 75% RH, respectively. Storage 
containers containing phosphorus pentoxide (P2O5) were used to represent the 0% RH. 
Supersaturated NaCl solution was used to provide the 75% RH. A stability incubator (Genlab 
incubator, Genlab Ltd, Cheshire, UK) was used to provide the 40 ̊C condition. All samples 
were stored for 3 months and tested periodically.   
 
Characterization of HMIM aged solid dispersions 
Scanning Electron Microscopy (SEM) 
For the purpose of comparison, fresh and aged samples at different conditions were scanned 
using JSM 5900LV Field Emission Scanning Electron Microscope (Jeol Ltd, Japan) equipped 
with a tungsten hairpin electron gun. Surfaces and cross sections (prepared by cutting the 
samples after dipping into liquid nitrogen) of all samples were investigated for the presence or 
absence of crystal growth and changes in the microstructure of the matrices. The scanned 
samples were coated with gold using a Polaron SC7640 sputter gold coater (Quorum 
Technologies, Newhaven, UK) prior to imaging.  
 
Energy-Dispersive X-ray Spectroscopy (EDS) 
In order to confirm the chemical identity of the detected crystal growth, the presence of the two 
chlorine atoms in the structure of felodipine were used as a chemical marker for the 
identification of drug crystals. EDS (INCA Energy manufactured by Oxford Instruments) 
combined with SEM was used. The analyses were conducted using single point X-ray 
acquisition mode with at least 3 points were analyzed for each morphological feature (crystals, 
matrix surface, matrix cross section) in the scanned area ≈ 0.5 x 0.5 cm2 of the sample. The 
acquisition time was 30 seconds with electron acceleration voltage was 20 kV.  
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Powder X-Ray Diffraction (PXRD) 
The diffraction patterns of the fresh and the aged samples were analyzed using Thermo ARL 
Xtra X-ray diffractometer (Thermo Scientific, Switzerland) equipped with a copper X-ray Tube 
(λ =1.540562 Å). An X-ray beams with a voltage of 45 kV and a current of 40 mA. The angular 
scan range was (5 ˚ < 2Ɵ < 60 ˚) using a step-scan mode with step width of 0.01˚ and scan 
speed of 1 sec/step were used to acquire the diffraction patterns.  
 
Attenuated Total Reflectance Fourier Transform Infrared Spectroscopy (ATR-FTIR) 
All samples were scanned using an IFS 66/S FTIR spectrometer (Bruker Optics Ltd, Coventry, 
UK) fitted with a Golden Gate® ATR accessory. The acquired ATR-FTIR spectra, in 
absorbance mode, were obtained using a scanning resolution of 2 cm-1 and 32 scans for each 
sample. Three replicate were performed for each formulation.  
Differential Scanning Calorimetry (DSC)  
A Q-2000 MTDSC (TA Instruments, Newcastle, USA) equipped with a RC90 cooling unit was 
used to analyze the placebo and felodipine loaded patches. A scanning rate of 10 ºC/min was 
used for all samples. The DSC was fully calibrated prior to the sample measurements. Three 
replicates of 2-3 mg of each sample taken randomly were analyzed using standard Aluminum 
TA crimped pans (TA Instruments, Newcastle, USA). Universal Analysis software was used 
to analyze the collected thermograms.  
 
Thermogravimetric Analysis (TGA) 
In order to estimate the loss of moisture content and thermal degradation profiles of the 
samples, raw materials, placebos and drug-loaded solid dispersions were analyzed using TGA 
Q5000 (TA Instruments, Newcastle, USA). A heating rate of 10 ºC/min was used for all 
 
 
9 
 
samples. Each sample was tested in triplicate. Universal Analysis software was used to analyze 
the acquired results.  
 
Statistical Analysis 
The results obtained using EDS and DSC were statistically analyzed using one-way analysis 
of variance (ANOVA). Differences of p < 0.05 were considered to be significant. 
 
Results  
Effects of the surfactants on the stabilities of semi-crystalline carriers in the placebo patches 
CM1 contains a liquid (at ambient temperature) surfactant, Tween 80 and CM2 contains a solid 
surfactant, TPGS. The addition of surfactant to the semi-crystalline mixture of PEG and PEO 
resulted in the formation of an extra phase. As seen in Figure 1, in the fresh placebos both 
Tween and TPGS were phase separated as indicated by their detectable endothermic melting 
peaks (as peak temperature) at -10.3 ± 0.2 and 37.5 ± 0.1 °C, respectively. When PEG and PEO 
were extruded without the surfactants at the ratio of 4:3 (w/w), which is the ratio used in the 
patches, a single melting with a peak temperature of 69.5 ± 1.5 °C (Supplementary Material 
Figure S1) was observed.  As seen in Figure 1, the DSC results of the placebo patches also 
show single melting transitions lower than the melting of PEG/PEO extrudates at 63.6 ± 0.2 
°C and 64.1 ± 0.3 °C for CM1 and CM2, respectively. The depressions of PEG/PEO melting 
temperature may indicate some degree of miscibility between the surfactants and the polymers. 
However, the melting enthalpy values of the fresh surfactant-containing placebo patches 
(178.96 ± 0.60 J/g for fresh CM1 and 178.10 ± 3.01 J/g for fresh CM2) are significantly higher 
than the enthalpy values of the pure PEG/PEO extrudates (154.30 ± 5.83 J/g). This could be 
due to the formation of the folded form of the metastable folded polymorphs of PEG and PEO 
that have lower melting points and have been reported to be induced by additives to PEG and 
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PEO (Dordunoo et al., 1997; Verheyen et al., 2001). 
 
After 3-month aging, no morphological change was observed except CM1 patches liquefied 
under condition D. TGA results of the CM1 placebo stored under condition D show 
continuously weight loss from 20 °C (Figure 2A), whereas the samples stored at other aging 
conditions only show significant weigh loss at the thermal decomposition temperatures of the 
excipients around 370 °C (Figure 2B). The gradual weight loss at low temperatures may be 
attributed to the loss of low molecular weight degradation products during heating. Tween and 
PEG/PEO have been reported to go through thermally initiated autoxidation in literature (Ha 
et al., 2002; Han et al., 1995; Kerwin, 2008; Kishore et al., 2011; Lai and Liau, 2003). The 
presence of high humidity and temperature (as condition D) could accelerate this degradation 
process and generate a range of degradation products. The DSC results of the aged CM1 
placebos indicate no changes of the patches aged under condition A, B and C. However, no 
PEG/PEO melting was detected in the patches aged under condition D (Figure 1A). This again 
supported the hypothesis of degradation of CM1 placebo under condition D.  
 
Similar to the aged CM1 placebos, the DSC results indicate good stability of CM2 placebo 
under conditions A, B and C (Figure 1B). For CM2 patches aged under condition D, two 
additional shoulder peaks at 55 °C and 59.5 °C can be observed for PEG/PEO melting which 
may be attributed to a small extent of degradation of PEG/PEO. There are no changes in the 
melting behaviour of the TPGS phase. This result indicates that TPGS has better protective 
effect of the polymers from degradation during aging under high humidity and temperature.  
 
Effect of drug loading on the semi-crystalline carriers in fresh state 
After assessing the effect of the surfactant on the polymer, the effects of the incorporation of 
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drug on the surfactant-polymer carriers were investigated. The comparisons of the 
morphologies of the surfaces and cross-sections of the placebos and drug-loaded patches are 
shown in Figure 3. Drug loading leads to increased surface roughness of the fresh CM1 patches. 
The DSC results of the drug loaded CM1 samples show no melting of Tween. A shoulder at 
the onset of the melting of PEG/PEO developed with increasing the drug loading to 20 and 
30% (Figure 4 A and C). At 30% drug loading, a separate melting peak at 87 °C can be detected. 
This is assigned to the significantly depressed melting of crystalline felodipine, indicating of 
the presence of crystalline felodipine in CM1 patches with 30% drug loading CM1 patches. 
Single Tg’s were detected for all drug loaded fresh CM1 patches (at -49.0 ± 0.6, -38.0 ± 0.3 
and -46.6 ± 0.5 °C for 10, 20 and 30% drug loading, respectively). These Tgs are higher than 
the Tg of both Tween and PEG/PEO, but lower than the Tg of amorphous felodipine. Therefore, 
it is reasonable to assign these Tg to the amorphous phase containing Tween, drug and 
PEO/PEG. The decrease of Tg in fresh 30% CM1 indicates a smaller amount of drug in the 
amorphous phase and is consistent with the observed melting of crystalline drug in the samples. 
Interestingly, no melting of Tween 80 was detected in all fresh CM1 patches with 10-30% drug 
loading, whereas the melting of the phase separate Tween 80 phase can be clearly observed in 
the fresh CM1 placebo patches. This suggests that the incorporation of the drug disrupted the 
crystallization of Tween possibly due to the dissolution of drug in the Tween phase.  
 
The drug loaded fresh CM2 patches show the separate melting of the TPGS phase at 28.9 ± 
0.3, 20.4 ± 0.4 and 24.9 ± 1.5 °C for 10, 20, and 30% drug loaded systems, respectively. These 
melting are significantly lower than the melting of pure TPGS (37.2 ± 0.2 C̊) and the melting 
of the TPGS phase in the placebo patches. This indicates that certain amount of the drug was 
solubilized in the TPGS phase, which caused the significant depression of the TPGS melting 
compared to the pure TPGS. Assuming the lowering of melting point is an indicator of drug 
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solubility, it is clear that the 20% drug loaded system had more drug dissolved in the TPGS 
than 10 and 30% loaded systems. In contrast to CM1, no melting of felodipine is seen in the 
DSC results of the 30% drug-loaded CM2 samples. Despite there is the possibility of the 
dissolution of crystalline felodipine on heating during the DSC experiment, it is still valid to 
suggest based on this evidence that TPGS shows better drug solubilization/stabilization effect 
than Tween 20 in the fresh state. This is in good agreement with the PXRD data of the fresh 
samples. Lower level of crystalline drug was detected in patches with 10-30% loading indicates 
that CM2 is better at initially solubilizing felodipine than CM1.  
 
Carrier stability of drug loaded patches aged under 0%RH (conditions A and C) 
Two key thermal transition regions in the DSC results of the drug-loaded patches on aging 
were monitored, the Tg and the melting regions. As summarized in Table 1, for 10% drug 
loaded CM1 and CM2 patches stored under condition A, little changes were observed for the 
surfactant related thermal transitions. Being stored at 40 °C (condition C) resulted in the 
appearance of the phase separate Tween melting transition and increased TPGS melting point 
and enthalpy values. More changes in the PEG/PEO phases (increases in the melting points 
and enthalpy values) were identified in aged CM1 patches than CM2 patches for both condition 
A and C. These results indicate that even at 10% drug loading aged CM1 patches already 
showed more signs of phase separation of the surfactant and instability of the polymers than 
CM2 patches. The results also highlighted the influence of temperature on these instabilities.  
 
For the aged CM1 and CM2 patches with 20 and 30% drug loadings, both Tg and associated 
∆Cp values decreased. As discussed above, the single Tgs of the patches are indications of a 
mixed amorphous phase of carrier and the drug as the Tgs are higher than the Tg of the carrier 
and lower than the Tg of the amorphous drug. As the drug behaves as an anti-plasticizer, the 
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decreases in Tg values after aging are an indication of a reduction in amount of amorphous drug 
in the carrier rich phases. In addition,  melting of Tween 80 was detected in 20% CM1 stored 
under 40 ºC and 30% CM1 stored under both room temperature and 40 ºC. For CM2 patches, 
the melting point and enthalpy values of the TPGS phases were increased for both condition A 
and C. For both CM1 and CM2, the changes are greater for patches with 20% drug loading 
than the 30% samples. We discuss the implications of this observation in the section below 
concerning drug crystallization phenomena.  
 
New shoulder peaks (as highlighted by •) close to the offset regions of PEG/PEO melting of 
the 20% CM1 and CM2 samples stored at condition C were observed (Figure 4 A and C). As 
discussed earlier for the fresh 30% drug loaded CM1, these peaks are attributed to recrystallized 
drug into the aged samples. These crystalline drug related peaks are absent in the aged 30% 
drug loaded CM2 under both conditions A and C.  
 
For the aged 20 and 30% CM1 samples, the melting transitions of Tween (absent in fresh 
sample) are detectable  indicating Tween 80 phase separation except the 20% aged patches at 
condition A.  Tween 80 melting peaks were also undetectable for 10% CM1 samples stored at 
condition A. This indicates that higher storage temperature promotes the phase separation of 
the drug from the surfactant phase, which subsequently led to the detected melting of the 
crystallized Tween 80. 
 
For the aged CM2 patches, the melting peaks of TPGS phases shift to a higher temperatures 
which are closer to the melting point of pure TPGS (Figure 4 C and G) and show increased 
enthalpy of melting values (Table 1). This indicates more complete phase separation of TPGS 
which may also be due to the crystallization of drug from TPGS phase. The increase in the 
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melting temperature and the enthalpy of melting of the TPGS in the 30% drug-loaded patches 
is greater than that of the 20% drug-loaded patches. This implies more drug dissolved in the 
TPGS in the 20% sample than the 30% sample. It also should be mentioned that greater 
increases in the melting enthalpy values of the TPGS were seen in the DSC results of the 20 
and 30% loaded CM2 patches aged at 40 °C than at room temperature (Supplementary 
materials Tables S1 and S2) which again indicates that higher storage temperature have more 
significant effect on the stability and the process of the phase separation of the solid dispersions. 
Once the surfactants are phase separated in their crystalline form, lower amounts of drug are 
solubilized in the surfactant phases. This suggests that more crystalline drug is likely to be 
present in 30% drug loaded samples under condition C, consistent with our previous 
observations.  
 
Carrier stability of drug loaded patches under 75%RH (Condition B and D) 
Under 75% RH, for 10% drug-loaded CM1 and CM2 little change was observed (Table 1) for 
the surfactants and PEG/PEO related thermal transitions. For 20-30% drug loaded CM1 and 
CM2, the common features are decreased Tg and ΔCp values, accompanied by the increased 
melting enthalpy of the surfactant phases. The changes between conditions B and D are greater 
for CM2 than for CM1 indicating CM2 patches were more sensitive to humidity induced 
instability. This is further confirmed by the depressed melting of felodipine in aged CM2 
patches that was detected under both conditions B and D and which were absent in the samples 
aged under 0%RH. This indicates that high humidity led to more drug crystallization in TPGS 
containing samples. For CM2, a more significant effect of storage temperature on the stability 
is also demonstrated by comparison of the differences between the melting enthalpy of TPGS 
for the aged patches under conditions A and C and  conditions B and D (Supplementary 
materials Tables S1 and S2). The differences between A and C are greater than those between 
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A and B (in addition the differences between C and D are greater  than those between B and 
D) suggesting that the storage temperature has more impact on the instability of CM2 patches. 
For all patches aged under condition D, the development of multiple peaks on the melting peak 
of PEG/PEO were observed (Figure 4). We assign these to the melting of degradation products 
of PEG/ PEO due to the random chain scission of the two polymers caused by oxidative thermal 
degradation.  
 
Effect of surfactants on crystallisation tendency and crystal growth of felodipine on aging  
Felodipine can crystallize in a range of polymorphs due to the flexibility of its molecular 
structure (Akune et al., 2015; Surov et al., 2012). Since the determination of felodipine form I 
crystal structure in 1986, several studies have been published reporting new polymorphic forms 
(II-IV) obtained from various solvents (Lou et al., 2009; Mishra et al., 2014; Rollinger and 
Burger, 2001; Srčič et al., 1992; Surov et al., 2012; Wang et al., 2015). This part of the study 
focuses on the felodipine crystallization in the aged samples. Using SEM in combination with 
EDS the crystal growth of felodipine on and in the patches were monitored. Table 2 summarizes 
the drug crystallization and crystal habits after 3 months aging under the 4 different conditions. 
Except for the 20% CM1 stored at condition C and 10% CM2 stored at condition D, drug 
recrystallization occurred during aging in all formulations. Generally, more drug crystallization 
was observed on the surface of the patches and the interior of the air pockets than the bulk 
matrix of the samples. This is likely to be due to the surface being the hydrophobic (air exposed) 
interface experiencing highest temperature and humidity at least at the initial few hours of the 
aging process. These results are consistent with data reported in literature revealing faster 
surface to bulk drug crystallization (Wu and Yu, 2006; Zhu et al., 2008). There are three main 
types of felodipine crystal habits observed, blocks, plates and needles arranged in a spherulitic 
pattern (Figure 5). In literature the crystal habits of the polymorphs were reported to be block 
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shaped for polymorphs I and II and plate-like crystals for form III (Surov et al., 2012), but no 
information about the crystal habit of polymorph IV of felodipine (Mishra et al., 2014) is 
available. In this study the spherulitic crystals were only observed in the interior or on the 
surface after aging under 40 °C (condition C and D). The blocks and plate crystals are more 
common than the needle crystals and they were observed on the surfaces and interior of most 
formulations.  
 
In order to further identify the polymorphic form of the recrystallized felodipine, PXRD and 
ATR-FTIR were used to characterize the aged samples. Table 3 summarizes the identification 
of the polymorphs using PXRD and ATR-FTIR results. No PXRD detectable drug 
crystallization was observed in both 10% drug loaded CM1 and CM2 patches due to the low 
quantity of the crystalline materials. However, the observation of surface crystals for these 
samples by SEM (supplementary material Figure S2 and S3) may explain the detected presence 
of crystalline material in the ATR-FTIR spectra. As seen in Figure 6, the diffraction pattern of 
the aged 20% w/w CM1 patch under condition A indicates the presence of form I (Surov et al., 
2012). This is consistent with the SEM results as form I is the usually present in the block 
shaped habit (Mishra et al., 2014). The presence of mixture of form I and II was indicated in 
the PXRD pattern of the 20% drug loaded CM1 sample stored under condition B. It should be 
mentioned that Figure 6 only shows the section of the PXRD diffraction patterns of the samples 
that contain the smallest number of interfiling  polymer and surfactant peaks (13.6 ̊, 14.5 ̊, 15.1 ̊, 
17.2 ̊, 18.4 ̊ and 19.1 ̊). Under high storage temperature (condition C and D) new peaks at 9.3 ̊ 
and 12.4 ̊ are observed in the diffraction patterns of the aged patches. These diffraction peaks 
do not match with any known polymorphs of felodipine in the literature, suggesting the 
presence of an unknown new metastable polymorph. For 20% drug loaded CM2 samples, fewer 
recrystallization diffraction peaks with lower relative intensities were identified compared to 
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the corresponding CM1 loaded samples. This may again suggest the higher solubilization 
capacity and stabilization ability of TPGS containing CM2 matrices compared CM1 
formulations. However, it is interesting to observe the diffraction peaks at 9.3 ̊, and 12.4 ̊ in 
aged CM2 samples stored at all conditions. This indicates that the CM2 matrices promote the 
crystallization of the metastable new form.   
 
For the 30% drug loaded samples (Figure 7), it is noted that form I felodipine is present in fresh 
CM1. The polymorph of the drug in the fresh CM2 was not identified due to weak diffraction 
peaks and broad IR peaks. The diffraction patterns of the aged 30% drug-loaded CM1 samples 
under all conditions indicate the coexistence of the new form and form I. However, it is noted 
that regardless of the humidity, room temperature storage resulted in the higher yield of the 
form I than the new form as indicated by the relative intensities of peaks at 9.3 ̊ (corresponding 
to the new form) and at 10.8 ̊ (corresponding to form I). For 30% w/w CM2 formulations, 
storing under 0% RH led to the crystallization of form I; whereas the sample stored under 75% 
RH led to the crystallization of the new metastable form. This is supported by the new NH 
stretching of the samples that is different from the NH peak of form I.  
 
Figure 8 displays the NH stretching vibration in the IR spectra of the aged 20 and 30% drug 
loaded CM1 and CM2 patches. NH stretching peaks at 3339 cm-1, 3372, 3334, 3370, 3329 cm-
1 have been reported for the identification of the amorphous and four crystalline polymorphic 
forms I-IV, respectively (Konno and Taylor, 2006; Lou et al., 2009; Rollinger and Burger, 
2001; Srčič et al., 1992; Tang et al., 2002; Wang et al., 2015). Whilst other peaks do vary with 
form, these are the clearest and have least interference from the matrix peaks (Konno and 
Taylor, 2006; Tang et al., 2002).  The spectra must be used with caution as the sample size is 
less than the total size of the patch and where crystals are formed they are necessarily regions 
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of inhomogeneity with a drug rich region adjacent to drug poor regions. In the case of limited 
surface crystallisation this situation is exacerbated. Since in ATR-FTIR the penetration of the 
evanescent wave is of the order of micron crystals at the surface will be preferentially sampled 
(Campbell, 2012). This can result in the appearance of apparently high concentrations of the 
crystalline forms and explains the observations of a signal from crystals in the 10% samples 
where none were observed in PXRD. Using these signature peaks, it is possible to confirm the 
identification of the polymorphic forms detected by PXRD. CM1 samples stored at condition 
C and D and CM2 samples stored at all conditions revealed an new NH stretching peak at 3321 
cm-1 which is not related any known polymorphs or the amorphous form. As the PXRD results 
indicated that the growth of the new form is favoured at 40 ̊C, it is reasonable to suggest that 
the NH stretching peak at 3321 cm-1 is a possible signature peak for a new polymorphic crystal 
form of felodipine. The ATR-FTIR results (Figure 8) show good agreement with PXRD data. 
 
In summary it is clear that the growth of the new polymorphic form is favoured by TPGS 
containing dispersions when the drug loading is close to saturation (20% loading). When form 
I is already present in the fresh samples, the growth of the new form is more favoured by higher 
storage temperature but is not sensitive to humidity.  
 
Discussion 
This study investigated the stability of multi-component solid dispersions. Some 
inconsistencies of SEM, PXRD and IR results were observed. These are likely to be caused by 
the effect of sampling on the results obtained by different characterisation methods (Grisedale 
et al., 2011). Nevertheless from the data, two general observations can be summarized. 1) For 
both 0% and 75% RH, it is clear that storage at 40 °C led to a greater degree of phase separation 
than storage at room temperature. The observation that temperature had a greater effect on 
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stability than humidity suggests that key factor may be molecular mobility which is enhanced 
more by higher temperatures than water absorption. Another possibility is that the phase 
diagram for the system will be temperature dependent and the shift in phase relations could be 
due to changes in the relative solubilities with temperature.  However we consider this is 
unlikely as the observed changes are of increased phase separation whereas the most likely 
effect of temperature on phase relations is to increase solubility. 2) For both CM1 and CM2, 
drug loading has significant impact on the aging behavior of the carrier materials. The CM1 
and CM2 patches with 20% drug loading, which is at the boundary of the saturation point 
saturation of drug solubility in the carrier materials, showed the highest drug phase separation 
activity of the patches on aging. The patches with drug loadings below and above the saturation 
point showed less phase separation highlighting the important relationship between the degree 
of saturation and stability. 
 
In order to make a more quantitative comparison of the changes observed the following process 
as used: normalisation was conducted by dividing the value of each thermal parameter for a 
given transition (e.g. Tween Tg or TPGS ∆Hf) by the sum of all the values for that transition 
across all storage conditions and drug loadings (including zero drug loading) during the 3-
month aging period. This ensured the values across all the sets had the same order of magnitude 
so that changes were much easier to compare. Within particular data sets changes were 
quantified by calculating the statistical variance within the set. Normalized values of ∆Cp 
values and ∆Hf for TPGS and Tween are shown in Figure 9. ∆Cp is a measure of the amount of 
amorphous material thus the variation of ∆Cp during ageing represents changes in the amount 
of amorphous materials in the samples. As seen in Figure 9a, CM2 samples show a greater 
difference in ∆Cp between fresh and aged samples than CM1 samples. After aging, significant 
reductions in ∆Cp TPGS indicate the decreases in the amorphous TPGS contents in particular 
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for 20 and 30% drug loaded samples. The ∆Hf data of the aged CM2 samples in Figure 9b show 
increases after aging indicating increased phase separation of crystalline TPGS. 
 
The smaller fluctuations in the ∆Cp values of the fresh and aged Tween samples for all drug 
loadings in comparison to the TPGS samples indicates a smaller change in the amount of 
amorphous Tween in the fresh and aged samples. The ∆Hf data of the Tween samples revealed 
that more crystalline Tween is generated after aging for most of the samples. The amount of 
the crystalline Tween increases with increasing the drug loading. Whilst generally increases in 
∆Cp correspond to decreases in ∆Hf representing the transfer of material from an amorphous 
mixed phase to a single component phase the correlation is variable. This may be the effect of 
the variability of the amounts of dissolved drug in the amorphous phase causing changes in the 
intrinsic change in heat capacity at the glass transition 
 
In order to further analyze the effect of storage, the variance of the set of parameters were 
calculated across the set of storage conditions for each drug loading. This gives direct measure 
of the size of the effect of storage condition. Figure 10a summarizes the influence of the 
surfactants on the thermal behaviour of PEG/PEO and highlights that TPGS has a stronger 
effect on the PEG/PEO behaviour of the aged formulations than Tween 80. Figure 10b 
demonstrates that the aging effects on TPGS thermal behaviour in CM2 is greater than that of 
Tween in CM1. In particular, more profound changes of the 20% loaded CM2 samples on aging 
demonstrated the importance of the relationship between drug-carrier solubility and stability. 
Boundary solubility should be avoided to minimize the instability associated with drug 
recrystallization. As seen in Figure 10a, the variances in PEG/PEO thermal behaviour during 
the aging period under all conditions are very much less than the ones observed for the thermal 
data of the surfactants.  This indicates that the aging affects the stability of the surfactant phase 
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more than the PEG/PEO phase. If the surfactants and PEG/PEO are well mixed, this would not 
be case. Therefore this result suggests that in both CM1 and CM2 formulations the surfactants 
are largely phase separate from the PEG/PEO phase. However the scale of phases could not be 
concluded from the data of this study.   
 
In addition, the chemical stability of the PEG/PEO based carrier material should also be 
carefully considered during formulation. In comparison to Tween containing CM1 samples, 
TPGS containing CM2 samples is much less vulnerable to degradation owing to the antioxidant 
activity of TPGS (Brouwers et al., 2006; Cagno et al., 2012; Carini et al., 1990; Crowley et al., 
2002). For drug loaded CM1 patches, less signs of degradation of PEG/PEO were observed 
under high temperature and high humidity environments in comparison to placebos suggesting 
the drug incorporation also had protective effect to the carrier material from degradation, most 
likely to be antioxidation (Sugawara et al., 1996).  
 
Conclusions 
This study has investigated the effect of surfactants on the stability of multi-component 
dispersions which were intentionally formulated being phase separate. Semi-solid surfactant 
TPGS showed better stabilizing effect on the drug than the liquid surfactant Tween 80. The 
higher Tg and semi-solid nature of TPGS which provides higher viscosity in the dispersion are 
believed to contribute to its higher stabilising effect of the model drug. However, such 
stabilizing effect is only valid for the systems with drug loading below the saturation of drug 
in the carrier. With drug loading at the border and above the saturation, the stabilization 
advantage is significantly reduced. This correlation between the drug saturation level in the 
carrier materials and the overall formulation stability agrees well with literature data and can 
be applied to other solid dispersions in general. In addition, a new polymorphic form of 
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felodipine was observed in the aged samples. The crystallization of the new form is more 
sensitive to temperature than humidity and TPGS proved to be a good aid for the crystallization 
of the new form. We believe that the stability study methodology established in this study can 
be used in the studies of other multi-components solid dispersions systems.  
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Figure 1. DSC thermograms of placebo (A) CM1 and (B) CM2 patches (with a scanning rate of 10 ̊C/ min). 
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Figure 2. TGA results of  (A) 3-month aged CM1 placebo patches and (B) raw materials (with a heating rate of 10 ̊ C/min).   
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Figure 3. SEM of micro-structural changes of the placebo and 20% drug loaded patches before and after 3-month aging under 40°C/75%RH.  
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Figure 4.  DSC results of 20% drug loaded CM1 patches: (A) PEG/PEO melting and (B) Tg regions; 20% drug loaded CM2 patches: (C) PEG/PEO 
melting and (D) Tg regions; 30% drug loaded CM1 patches: (E) PEG/PEO melting and (F) Tg regions; and 30% drug loaded CM2 patches: (G) 
PEG/PEO melting and (H) Tg regions.  
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Figure 5. Representative SEM images of different felodipine crystal habits: blocky & plate crystals in (a) in 30% CM1 condition B surface and 
(b) 30% CM2 condition C interior; needle and plate crystals in (c) 10% CM2 condition C surface and (d) 20% CM1 condition B; fine needle 
crystals in (e) 30% CM1 condition D surface and (f) interior; and thick needle crystals in (g) 30% CM2 condition D surface and (h) interior. 
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Figure 6. PXRD patterns of 20% w/w drug loaded fresh and 3-month aged (A) CM1 and (B) CM2 patches. 
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Figure 7. PXRD patterns of 30% w/w drug loaded fresh and 3-month aged (A) CM1 and (B) CM2 patches. 
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Figure 8. Partial ATR-FTIR spectra of the fresh and aged (A) 20% drug loaded CM1 patches, (B) 20% drug-loaded CM2 patches; (C) 30% drug 
loaded CM1 patches and (D) 30% drug-loaded CM2 patches.  
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Figure 9 Normalized thermal data of (a) ∆Cp and (b) ∆Hf of Tween and TPGS in the fresh and 3-month aged patches. A, B, C and D refer to the 
4 different storage conditions. 
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Figure 10. Variances of the thermal values of (a) PEG/PEO and (b) Tween and TPGS during the 3-month of aging under different conditions 
(note the large differences in scale between the PEG/PEO values and the surfactant values). 
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Table 1. Summary of the changes of thermal properties of the aged patches in comparison to the properties of the fresh patches 
 
Formulation 
  Tg ∆Cp PEG/PEO Tm PEG/PEO ∆Hf Surfactant Tm Surfactant ∆Hf 
  A B C D A B C D A B C D A B C D A B C D A B C D 
CM1 
(Tween) 
0            *    *    *    * 
10                  ♦ ♦   ♦ ♦  
20                  ♦ ♦ ♦  ♦ ♦ ♦ 
30                 ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ 
CM2 
(TPGS) 
0                         
10                         
20                         
30                         
 
(*) stands for the sample liquefied after 3 months storage and not testable 
() value increased in comparison to fresh samples 
() value decrease in comparison to fresh samples 
() value shows no significant change in comparison to fresh samples 
(♦) value decreased in comparison to pure Tween 80 (due to undetectable Tween 80 melting peak in the fresh samples) 
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Table 2. Summary of surface morphology and crystal growth of the 3-month aged HMIM 
patches obtained by SEM 
 
 
Drug 
loading 
(% w/w) 
Formulation CM1 (with Tween 80) CM2 (with TPGS) 
Location Surface Cross-section Surface Cross-section 
Ageing 
condition 
A B C D A B C D A B C D A B C D 
10 
Fresh - - - - 
Aged B B B+S S - - - - P B P - - - - - 
20 
Fresh P - - - 
Aged P P - S - - - - B B P S - - - S 
30 
Fresh B P+S - - 
Aged B B S S S B+S S S B B B S B B B S 
(S) Spherulitic crystals 
(B) Block shaped crystals 
(P) Plate crystals  
(-) No crystals were detected 
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Table 3. Crystal polymorphs identification of aged patches determined by PXRD and ATR-
FTIR. 
 
Formulations 
 
CM1 CM2 
Drug loading 
(% w/w) 
Storage 
conditions 
 
A B C D A B C D 
10 
 
Fresh - - 
Aged 1 1 - - - - - - 
20 
 
Fresh - NF 
Aged 1 1,2 NF NF NF 1,NF 1,NF 1,NF 
30 
 
Fresh 1 * 
Aged 1 1,NF 1,NF 1,NF 1 1 1 NF 
 
(-) No crystalline drug detected 
(1) Felodipine polymorphic I 
(2) Felodipine polymorphic II 
(NF) New polymorphic form that does not match the PXRD and IR data of any polymorphic 
form reported in the literature 
(*) Broad IR peaks and weak PXRD diffraction peak did not allow identification  
 
